Patheon NV Company Profile (NASDAQ:PTHN)

About Patheon NV (NASDAQ:PTHN)

Patheon NV logoPatheon N.V. is a provider of outsourced pharmaceutical development and manufacturing services. The Company's segments include Drug Product Services (DPS), Pharmaceutical Development Services (PDS) and Drug Substance Services (DSS). The DPS segment is engaged in manufacturing and packaging for approved prescription, over-the-counter (OTC) and nutritional products. The PDS segment provides a range of formulation, production and technical services from the early stages of a product's development to regulatory approval, as well as for new formulations of approved products for lifecycle extension. The DSS segment provides small molecule active pharmaceutical ingredient (API) and outsourced manufacturing solutions for large molecule biological API from early development through commercial scale production. It provides an integrated range of API and finished drug product services to its customers, from formulation development to clinical and commercial-scale manufacturing.

Industry, Sector and Symbol:
  • Sector: N/A
  • Industry: N/A
  • Sub-Industry: N/A
  • Symbol: NASDAQ:PTHN
  • CUSIP: N/A
  • Web: N/A
  • Market Cap: $5.01 billion
  • Outstanding Shares: 145,136,000
Average Prices:
  • 50 Day Moving Avg: $28.60
  • 200 Day Moving Avg: $28.56
  • 52 Week Range: $23.72 - $34.84
  • Trailing P/E Ratio: 56.09
  • Foreward P/E Ratio: 23.19
  • P/E Growth: 1.57
Sales & Book Value:
  • Annual Revenue: $1.92 billion
  • Price / Sales: 2.61
  • Book Value: ($2.11) per share
  • Price / Book: -16.37
  • EBIDTA: $359.6 million
  • Average Volume: 1.41 million shs.
  • Short Ratio: 5.95

Frequently Asked Questions for Patheon NV (NASDAQ:PTHN)

What is Patheon NV's stock symbol?

Patheon NV trades on the NASDAQ under the ticker symbol "PTHN."

How were Patheon NV's earnings last quarter?

Patheon NV (NASDAQ:PTHN) issued its quarterly earnings data on Thursday, March, 16th. The company reported $0.14 EPS for the quarter, missing the Thomson Reuters' consensus estimate of $0.22 by $0.08. The business had revenue of $457.40 million for the quarter, compared to analyst estimates of $463.39 million. Patheon NV's revenue for the quarter was up 12.7% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.08) EPS. View Patheon NV's Earnings History.

Where is Patheon NV's stock going? Where will Patheon NV's stock price be in 2017?

12 brokerages have issued twelve-month target prices for Patheon NV's shares. Their forecasts range from $28.00 to $35.00. On average, they expect Patheon NV's share price to reach $31.80 in the next twelve months. View Analyst Ratings for Patheon NV.

What are analysts saying about Patheon NV stock?

Here are some recent quotes from research analysts about Patheon NV stock:

  • 1. According to Zacks Investment Research, "Patheon N.V. is a provider of pharmaceutical development and manufacturing services. Patheon N.V. is based in Amsterdam, Netherlands. " (5/19/2017)
  • 2. Jefferies Group LLC analysts commented, "PTHN's results are a further indication of inherent volatility in the CMO business despite long-cycle contracts. FY17 guidance was reduced on FX headwinds and project delays partially offset by the Roche facility acquisition. LT indicators were more positive and we still believe PTHN can generate above industry growth." (3/17/2017)
  • 3. Morgan Stanley analysts commented, "High operating leverage can drive ~330 bps in EBITDA margin expansion by FY18; we see EPS growth of 58 percent/20 percent in FY17/FY18," analyst Ricky Goldwasser wrote in a note.Goldwasser said the company is poised to expand its CMO share due to its open platform, end-to-end service, quality and global footprint.Related Link: Wells Fargo Initiates Coverage On Patheon At OutperformForward ViewAs such, the analyst believes Patheon can grow its top line at an 11 percent/8 percent CAGR in FY17/FY18, above market growth rates of 5–6 percent, with 209 bps and 121 bps in EBITDA margin expansion in FY17/FY18. The analyst estimates Patheon can grow EBITDA margins from 21.6 percent in FY16 to 24.8 percent in FY18."Patheon is poised to thrive on biologics, the fastest growing area in drug development, given capabilities that span formulation / development as well as API," (8/15/2016)

Who are some of Patheon NV's key competitors?

Who are Patheon NV's key executives?

Patheon NV's management team includes the folowing people:

  • Paul S. Levy, Chairman of the Board
  • James C. Mullen, Chief Executive Officer, Director
  • Stuart R. Grant, Chief Financial Officer, Executive Vice President
  • Gilles A. Cottier, President - Global Pharmaceutical Development Services
  • Franco Negron, President - Drug Product Services
  • Lukas Utiger, President - Drug Substance
  • Michael J. Lehmann, Executive Vice President - Global Sales and Marketing
  • Michael E. Lytton J.D., Executive Vice President - Corporate Development and Strategy
  • Rebecca Holland New, Chief Human Resources Officer and Executive Vice President - Communications and Project Management Office
  • Harry R. Gill III, Senior Vice President - Quality and Continuous Improvement

When did Patheon NV IPO?

(PTHN) raised $625 million in an IPO on Thursday, July 21st 2016. The company issued 30,500,000 shares at $19.00-$22.00 per share. J.P. Morgan, Morgan Stanley, Jefferies, UBS Investment Bank, Credit Suisse, Evercore ISI and Wells Fargo Securities acted as the underwriters for the IPO and Baird, Piper Jaffray, Raymond James, William Blair, KeyBanc Capital Markets and Leerink Partners were co-managers.

Who owns Patheon NV stock?

Patheon NV's stock is owned by a number of of retail and institutional investors. Top institutional investors include JLL ASSOCIATES G.P. V (PATHEON), LTD. (43.10%), Wellington Management Group LLP (3.17%), JPMorgan Chase & Co. (2.53%), TimesSquare Capital Management LLC (1.34%), Ameriprise Financial Inc. (1.24%) and Eagle Asset Management Inc. (0.85%). Company insiders that own Patheon NV stock include Jll Patheon Co-Investment Fund, Pamela Daley, Paul S Levy and Philip Eykerman. View Institutional Ownership Trends for Patheon NV.

Who sold Patheon NV stock? Who is selling Patheon NV stock?

Patheon NV's stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Acadian Asset Management LLC, Janus Capital Management LLC, Columbus Circle Investors, TIAA CREF Investment Management LLC, American Century Companies Inc., Pier Capital LLC and BlueMar Capital Management LLC. View Insider Buying and Selling for Patheon NV.

Who bought Patheon NV stock? Who is buying Patheon NV stock?

Patheon NV's stock was acquired by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, OppenheimerFunds Inc., Ameriprise Financial Inc., Schroder Investment Management Group, Redmile Group LLC, Zweig DiMenna Associates LLC, MARSHALL WACE ASIA Ltd and Marshall Wace North America L.P.. Company insiders that have bought Patheon NV stock in the last two years include Jll Patheon Co-Investment Fund, Pamela Daley, Paul S Levy and Philip Eykerman. View Insider Buying and Selling for Patheon NV.

How do I buy Patheon NV stock?

Shares of Patheon NV can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Patheon NV's stock price today?

One share of Patheon NV stock can currently be purchased for approximately $34.55.

MarketBeat Community Rating for Patheon NV (NASDAQ PTHN)
Community Ranking:  3.3 out of 5 (  )
Outperform Votes:  55 (Vote Outperform)
Underperform Votes:  28 (Vote Underperform)
Total Votes:  83
MarketBeat's community ratings are surveys of what our community members think about Patheon NV and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Patheon NV (NASDAQ:PTHN) (?)
Ratings Breakdown: 5 Hold Ratings, 7 Buy Ratings
Consensus Rating:Buy (Score: 2.58)
Consensus Price Target: $31.80 (7.96% downside)

Analysts' Ratings History for Patheon NV (NASDAQ:PTHN)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/16/2017Jefferies Group LLCDowngradeBuy -> Hold$32.00 -> $35.00LowView Rating Details
5/15/2017Evercore ISIDowngradeOutperform$35.00LowView Rating Details
5/15/2017William BlairDowngradeOutperform -> Market PerformLowView Rating Details
5/15/2017Piper Jaffray CompaniesDowngradeOverweight -> NeutralLowView Rating Details
3/17/2017Robert W. BairdDowngradeOutperform -> Neutral$34.00 -> $28.00LowView Rating Details
11/10/2016Leerink SwannInitiated CoverageOutperform$31.00N/AView Rating Details
8/16/2016Credit Suisse Group AGInitiated CoverageNeutral$30.00N/AView Rating Details
8/15/2016Raymond James Financial, Inc.Initiated CoverageOutperform$32.50N/AView Rating Details
8/15/2016Wells Fargo & CoInitiated CoverageOutperformN/AView Rating Details
8/15/2016Morgan StanleyInitiated CoverageOverweight$31.00N/AView Rating Details
8/15/2016KeyCorpInitiated CoverageOverweight$33.00N/AView Rating Details
8/15/2016JPMorgan Chase & Co.Initiated CoverageOverweight$30.00N/AView Rating Details
(Data available from 5/29/2015 forward)


Earnings History for Patheon NV (NASDAQ:PTHN)
Earnings by Quarter for Patheon NV (NASDAQ:PTHN)
Earnings History by Quarter for Patheon NV (NASDAQ:PTHN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/16/20171/31/2017$0.22$0.14$463.39 million$457.40 millionViewN/AView Earnings Details
12/20/2016Q416$0.39$0.30$496.27 million$510.20 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Patheon NV (NASDAQ:PTHN)
2017 EPS Consensus Estimate: $1.36
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172$0.19$0.22$0.21
Q2 20172$0.29$0.37$0.33
Q3 20171$0.38$0.38$0.38
Q4 20172$0.42$0.46$0.44
(Data provided by Zacks Investment Research)


Dividend History for Patheon NV (NASDAQ:PTHN)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Patheon NV (NASDAQ:PTHN)
Insider Trades by Quarter for Patheon NV (NASDAQ:PTHN)
Institutional Ownership by Quarter for Patheon NV (NASDAQ:PTHN)
Insider Trades by Quarter for Patheon NV (NASDAQ:PTHN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/30/2016Paul S LevyDirectorBuy10,000$29.55$295,500.00View SEC Filing  
9/28/2016Paul S LevyDirectorBuy15,000$29.64$444,600.00View SEC Filing  
9/12/2016Paul S LevyDirectorBuy37,000$28.01$1,036,370.00View SEC Filing  
7/26/2016Jll Patheon Co-Investment FundMajor ShareholderBuy815,730$19.85$16,192,240.50View SEC Filing  
7/26/2016Pamela DaleyDirectorBuy48,800$19.85$968,680.00View SEC Filing  
7/21/2016Philip EykermanDirectorBuy28,000$25.00$700,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Patheon NV (NASDAQ:PTHN)
Latest Headlines for Patheon NV (NASDAQ:PTHN)
DateHeadline logoPatheon NV (PTHN) Receives Consensus Recommendation of "Buy" from Brokerages - May 22 at 6:20 PM logoPatheon NV (PTHN) Expected to Announce Quarterly Sales of $465.97 Million - May 21 at 6:36 PM logoRoyal DSM N.V. -- Moody's changes Royal DSM's outlook to stable from negative; affirms A3/P-2 ratings - May 19 at 12:13 PM logoPatheon NV (PTHN) Upgraded to "Buy" at Zacks Investment Research - May 19 at 7:32 AM logoPatheon Holdings I B.V. -- Moody's places ratings of Patheon Holdings I B.V. on review for upgrade - May 17 at 7:18 PM logoNBPE Announces Valuation Uplift Following the Announced Acquisition of Patheon - May 17 at 8:22 AM logoPatheon NV (PTHN) Downgraded by Jefferies Group LLC to Hold - May 16 at 10:04 PM logoPatheon NV breached its 50 day moving average in a Bullish Manner : PTHN-US : May 16, 2017 - May 16 at 7:04 PM logoThermo Fisher Scientific (Finance I) B.V. -- Moody's affirms Thermo Fisher Scientific's Baa2 senior unsecured rating following Patheon acquisition announcement - May 16 at 7:03 PM logoPTHN Crosses Above Average Analyst Target - May 16 at 9:44 AM logoPatheon NV (PTHN) Expected to Announce Earnings of $0.16 Per Share - May 16 at 9:20 AM logoS&P 500, Nasdaq Composite hit record-highs - May 15 at 6:36 PM logoThermo Fisher to buy Patheon for $5.2 billion to expand biopharma services - May 15 at 6:36 PM logoPiper Jaffray Companies Lowers Patheon NV (PTHN) to Neutral - May 15 at 5:02 PM logoPatheon NV (PTHN) Stock Rating Lowered by William Blair - May 15 at 5:02 PM logoPatheon NV (PTHN) Downgraded by Evercore ISI - May 15 at 4:28 PM logoThermo Fisher Extends Binge With $5.2 Billion Patheon Deal - May 15 at 9:45 AM logoThermo Fisher to buy Patheon in $5.2 billion deal - May 15 at 9:45 AM logoPatheon Completes Sterile Expansion Project at Greenville, NC Manufacturing Site - May 8 at 11:55 AM logoPatheon NV (PTHN) Expected to Announce Quarterly Sales of $465.92 Million - April 27 at 12:20 PM logoPatheon NV (PTHN) Given Average Rating of "Buy" by Analysts - April 25 at 5:51 PM logoZacks: Analysts Anticipate Patheon NV (PTHN) to Announce $0.16 Earnings Per Share - April 25 at 2:15 PM logoDPx Holdings B.V. -- Moody's assigns B2 to DPx Holding's term loan following repricing - April 14 at 6:57 PM logoPatheon NV (PTHN) Receives Average Recommendation of "Buy" from Analysts - March 31 at 1:11 PM logoPatheon Achieved More Outsourced New Drug Approvals Than Any Other Provider According to 2017 PharmSource CMO Scorecard - March 30 at 7:38 PM logoPatheon NV (PTHN) Downgraded by Zacks Investment Research to "Strong Sell" - March 28 at 8:10 AM logoPatheon NV (PTHN) Downgraded to "Strong Sell" at Zacks Investment Research - March 22 at 6:01 PM logoPatheon N.V. downgraded by KeyBanc Capital Mkts and Robert W. Baird - March 18 at 12:31 AM logoPatheon NV (PTHN) Cut to “Neutral” at Robert W. Baird - March 17 at 7:34 PM logoPatheon 1Q Earnings Missed Street Estimates (PTHN) - March 17 at 7:31 PM logoPatheon NV’s (PTHN) “Buy” Rating Reaffirmed at Jefferies Group LLC - March 17 at 5:42 PM logoPatheon 1Q Earnings Missed Analyst Estimates - March 16 at 8:08 PM logoEdited Transcript of PTHN earnings conference call or presentation 16-Mar-17 12:00pm GMT - March 16 at 8:08 PM logoPatheon NV (PTHN) Releases Quarterly Earnings Results, Misses Estimates By $0.08 EPS - March 16 at 10:43 AM logoPatheon Reports Fiscal 2017 First Quarter Results - March 16 at 8:24 AM logo6:36 am Patheon N.V. misses by $0.08, misses on revs; lowers FY17 guidance - March 16 at 8:24 AM logoPatheon Holdings misses Street 1Q forecasts - March 16 at 8:24 AM logoQ1 2017 Patheon NV Earnings Release - Before Market Open - March 16 at 8:24 AM logoPatheon NV (PTHN) Set to Announce Earnings on Thursday - March 15 at 8:19 AM logoPatheon to Announce First Quarter Fiscal Year 2017 Financial Results on March 16, 2017 - March 3 at 8:33 AM logoPatheon Named Supply Chain Resiliency Partner of the Year - March 2 at 7:30 PM logoPatheon Reaches Analyst Target Price - February 24 at 8:34 PM logoPATHEON N.V. Files SEC form 8-K, Completion of Acquisition or Disposition of Assets, Other Events, Financial Statemen - February 8 at 9:27 PM logoCORRECTING and REPLACING PHOTO Patheon Announces Completion of its Acquisition of State-of-the-Art Manufacturing Site - February 1 at 10:08 PM logoPatheon to Participate in the 35th Annual J.P. Morgan Healthcare Conference - January 4 at 3:18 PM logoInsiders Will Likely Move Pharmaceutical Company Patheon's Stock - December 30 at 7:42 PM logoPATHEON N.V. Financials - December 29 at 7:22 PM logoPATHEON N.V. Files SEC form 10-K, Annual Report - December 23 at 7:31 PM logoEdited Transcript of PTHN earnings conference call or presentation 20-Dec-16 1:00pm GMT - December 21 at 12:03 AM logoPatheon Reports Growth Across All Segments For Fourth Quarter; Provides Outlook for Fiscal Year 2017 - December 20 at 2:00 PM



Patheon NV (PTHN) Chart for Monday, May, 29, 2017

This page was last updated on 5/29/2017 by Staff